Sibrafiban
Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation[1][2][3].
Product Specifications
CAS Number
172927-65-0
Product Name Alternative
RO 48-3657
UNSPSC
12352005
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/sibrafiban.html
Purity
99.67
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(OCC)COC1CCN(C([C@@H](NC(C2=CC=C(/C(N)=N/O)C=C2)=O)C)=O)CC1
Molecular Formula
C20H28N4O6
Molecular Weight
420.47
References & Citations
[1]M Dooley, et al. Sibrafiban. Drugs. 1999 Feb;57 (2) :225-30; discussion 231-2.|[2]B Wittke, et al. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Br J Clin Pharmacol. 2000 Mar;49 (3) :231-9.|[3]Jeffrey T Billheimer, et al. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy. Thromb Res. 2002 Sep 15;107 (6) :303-17.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![GNAL Mouse Monoclonal Antibody [Clone ID: OTI6A2]](https://cdn.genprice.uk/products/937/68dd18bb061270361e908e55/imageurl/cf812963.webp)
